William Blair lowered shares of Diplomat Pharmacy (NYSE:DPLO) from an outperform rating to a market perform rating in a research report released on Monday morning, The Fly reports. William Blair also issued estimates for Diplomat Pharmacy’s Q4 2018 earnings at $0.22 EPS, FY2018 earnings at $0.79 EPS, Q1 2019 earnings at $0.20 EPS, Q2 2019 earnings at $0.21 EPS, Q3 2019 earnings at $0.20 EPS, Q4 2019 earnings at $0.22 EPS, FY2019 earnings at $0.83 EPS and FY2020 earnings at $0.93 EPS.
A number of other equities research analysts have also recently commented on DPLO. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a strong sell rating in a research note on Tuesday, November 27th. Mizuho lowered their target price on Diplomat Pharmacy to $18.00 and set a neutral rating on the stock in a research note on Friday, November 9th. Wells Fargo & Co lowered their target price on Diplomat Pharmacy from $23.00 to $16.00 and set a market perform rating on the stock in a research note on Thursday, November 8th. ValuEngine upgraded Diplomat Pharmacy from a sell rating to a hold rating in a research note on Tuesday, October 23rd. Finally, Robert W. Baird cut Diplomat Pharmacy from a neutral rating to an underperform rating and lowered their target price for the stock from $22.00 to $10.00 in a research note on Wednesday, November 7th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. Diplomat Pharmacy currently has an average rating of Hold and an average target price of $22.70.
DPLO opened at $13.20 on Monday. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58. The firm has a market cap of $997.22 million, a price-to-earnings ratio of 15.71 and a beta of 0.97. Diplomat Pharmacy has a 1 year low of $12.30 and a 1 year high of $28.74.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.21). The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. Diplomat Pharmacy’s revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.01 earnings per share. On average, analysts expect that Diplomat Pharmacy will post 0.8 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in DPLO. Capital International Investors bought a new stake in shares of Diplomat Pharmacy during the third quarter valued at about $99,092,000. FMR LLC increased its position in shares of Diplomat Pharmacy by 154.4% during the second quarter. FMR LLC now owns 2,798,440 shares of the company’s stock valued at $71,528,000 after buying an additional 1,698,341 shares during the period. Frontier Capital Management Co. LLC increased its position in shares of Diplomat Pharmacy by 84.1% during the third quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock valued at $68,619,000 after buying an additional 1,614,645 shares during the period. BlackRock Inc. increased its position in shares of Diplomat Pharmacy by 17.0% during the third quarter. BlackRock Inc. now owns 8,464,251 shares of the company’s stock valued at $164,292,000 after buying an additional 1,228,490 shares during the period. Finally, Matarin Capital Management LLC bought a new stake in shares of Diplomat Pharmacy during the third quarter valued at about $13,536,000. Institutional investors and hedge funds own 85.22% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Story: What are Closed-End Mutual Funds?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.